{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:23Z","timestamp":1786991483809,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hau Giang Pharmaceutical Joint Stock Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00797-y","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:04:19Z","timestamp":1783937059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of luseogliflozin for the management of type 2 diabetes mellitus in Vietnam: a Markov model analysis from the Vietnam social health insurance perspective"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-4145","authenticated-orcid":false,"given":"The Due","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Son","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc Trung","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Tuyet Mai","family":"Kieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Minh","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"797_CR1","doi-asserted-by":"crossref","unstructured":"He K-J, Wang H, Xu J, Gong G, Liu X, Guan H. Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021. Front Endocrinol. 2024;15.","DOI":"10.3389\/fendo.2024.1501690"},{"key":"797_CR2","unstructured":"International Diabetes Federation. Facts & figures: International Diabetes Federation\u2019s website. 2024. Available from: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"issue":"9","key":"797_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525\u201339.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"797_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5334\/aogh.2526","volume":"86","author":"NB Ngoc","year":"2020","unstructured":"Ngoc NB, Lin ZL, Ahmed W. Diabetes: What Challenges Lie Ahead for Vietnam? Ann Glob Health. 2020;86(1):1.","journal-title":"Ann Glob Health"},{"issue":"41","key":"797_CR5","doi-asserted-by":"publisher","first-page":"e31149","DOI":"10.1097\/MD.0000000000031149","volume":"101","author":"DH Phan","year":"2022","unstructured":"Phan DH, Vu TT, Doan VT, Le TQ, Nguyen TD, Van Hoang M. Assessment of the risk factors associated with type 2 diabetes and prediabetes mellitus: A national survey in Vietnam. Med (Baltim). 2022;101(41):e31149.","journal-title":"Med (Baltim)"},{"key":"797_CR6","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48:S181-S206.","DOI":"10.2337\/dc25-S009"},{"issue":"22","key":"797_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"797_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"key":"797_CR9","unstructured":"Vietnam Ministry of Health. Decision 5481\/QD-BYT on promulgating the professional document Guidelines for diagnosis and treatment of type 2 diabetes. 2020."},{"key":"797_CR10","unstructured":"Vietnam News. Health insurance hits 5-year target early with 95.2% population coverage 2026 Available from: https:\/\/vietnamnews.vn\/society\/1765648\/health-insurance-hits-5-year-target-early-with-95-2-population-coverage.html."},{"key":"797_CR11","unstructured":"Vietnam\u2019s Ministry of Health. Circular No. 20\/2022\/TT-BYT on the List of Medicines Covered by Health Insurance for Insured Participants. 2022."},{"issue":"3","key":"797_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","volume":"12","author":"H Seino","year":"2021","unstructured":"Seino H. Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. Diabetes Ther. 2021;12(3):863\u201377.","journal-title":"Diabetes Ther"},{"key":"797_CR13","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003."},{"key":"797_CR14","unstructured":"Vietnam\u2019s Ministry of Health. Decision No. 1315\/Q\u0110-BYT on the Guidelines for Reporting Pharmacoeconomic Evaluations. 2024."},{"key":"797_CR15","unstructured":"National Statistics Office of Vietnam. Consumer price index, gold price index and US dollar price index in December, fourth quarter and 2024: National Statistics Office\u2019s website (https:\/\/www.nso.gov.vn) 2024. Available from: https:\/\/www.nso.gov.vn."},{"key":"797_CR16","unstructured":"Vietnamnet Global. USD\/VND exchange rate surges in first month of 2024 2024. Available from: https:\/\/vietnamnet.vn\/en\/usd-vnd-exchange-rate-surges-in-first-month-of-2024-2245549.html."},{"key":"797_CR17","unstructured":"National Statistics Office of Vietnam. Socio-economic situation in the fourth quarter and 2024: National Statistics Office\u2019s website (https:\/\/www.nso.gov.vn) 2024. Available from: https:\/\/www.nso.gov.vn."},{"key":"797_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/DMSO.S145152","volume":"10","author":"NTD Le","year":"2017","unstructured":"Le NTD, Dinh Pham L, Quang Vo T. Type 2 diabetes in Vietnam: a cross-sectional, prevalence-based cost-of-illness study. Diabetes Metab Syndr Obes. 2017;10:363\u201374.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"797_CR19","unstructured":"Drug Administration of Vietnam. Public disclosure of expected wholesale drug prices. 2024. Available from: https:\/\/dichvucong.dav.gov.vn\/congbogiathuoc."},{"key":"797_CR20","unstructured":"Vietnam Social Security. Drug procurement results in 2024. 2024. Available from: https:\/\/quanlythuoc.vss.gov.vn\/kqdt."},{"issue":"11","key":"797_CR21","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.2337\/dc09-0959","volume":"32","author":"S Zoungas","year":"2009","unstructured":"Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068\u201374. https:\/\/diabetesjournals.org\/care\/article\/32\/11\/2068\/25964\/Combined-Effects-of-Routine-Blood-Pressure.","journal-title":"Diabetes Care"},{"issue":"1","key":"797_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12933-017-0574-y","volume":"16","author":"K Mohammedi","year":"2017","unstructured":"Mohammedi K, Woodward M, Marre M, et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):95.","journal-title":"Cardiovasc Diabetol"},{"key":"797_CR23","unstructured":"Yang JJ, Yu D, Wen W, et al. Association of diabetes with all-cause and cause-specific mortality in Asia: a pooled analysis of more than 1 million participants. JAMA Netw Open. 2019;2(4)."},{"issue":"3","key":"797_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2337\/diacare.28.3.617","volume":"28","author":"M Cusick","year":"2005","unstructured":"Cusick M, Meleth AD, Agr\u00f3n E, et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report 27. Diabetes Care. 2005;28(3):617\u201325.","journal-title":"Diabetes Care"},{"issue":"7","key":"797_CR25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, Kaspers S. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Adv Ther. 2017;34(7):1707\u201326.","journal-title":"Adv Ther"},{"issue":"3","key":"797_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10741-021-10083-z","volume":"27","author":"M Barbarawi","year":"2022","unstructured":"Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Al Kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2022;27(3):951\u201360.","journal-title":"Heart Fail Rev"},{"key":"797_CR27","unstructured":"Phung LT, Le DS, Pham HTK. Cost-utility analysis of empagliflozin in the treatment of type 2 diabetes mellitus in Vietnam. Vietnam Med J. 2024;540(2)."},{"issue":"7","key":"797_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2337\/diacare.22.7.1125","volume":"22","author":"U.K. Prospective Diabetes Study Group","year":"1999","unstructured":"U.K. Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22(7):1125\u201336.","journal-title":"Diabetes Care"},{"issue":"2","key":"797_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/03007995.2016.1257978","volume":"33","author":"H Shao","year":"2017","unstructured":"Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017;33(2):359\u201369.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"797_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/13696998.2019.1570220","volume":"22","author":"X Cai","year":"2019","unstructured":"Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ. 2019;22(4):336\u201343.","journal-title":"J Med Econ"},{"issue":"10","key":"797_CR31","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40273-023-01286-3","volume":"41","author":"X Li","year":"2023","unstructured":"Li X, Hoogenveen R, El Alili M, Knies S, Wang J, Beulens JWJ, et al. Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry. PharmacoEconomics. 2023;41(10):1249\u201362.","journal-title":"PharmacoEconomics"},{"key":"797_CR32","doi-asserted-by":"crossref","unstructured":"Reifsnider OS, Kansal AR, Gandhi PK, Cragin L, Brand SB, Pfarr E, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care. 2021;9(1).","DOI":"10.1136\/bmjdrc-2020-001313"},{"issue":"7","key":"797_CR33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","volume":"21","author":"AA Leech","year":"2018","unstructured":"Leech AA, Kim DD, Cohen JT, et al. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018;21(7):759\u201361.","journal-title":"Value Health"},{"issue":"1","key":"797_CR34","first-page":"107","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plann. 2020;35(1):107\u201314.","journal-title":"Health Policy Plann"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00797-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00797-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00797-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:16:29Z","timestamp":1786990589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00797-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00797-y","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a model-based economic evaluation conducted using secondary data derived from published literature, publicly available sources, and aggregated administrative data. No individual-level patient data were collected or analyzed, and no human participants were directly involved. Therefore, according to Vietnamese regulations on biomedical research ethics, approval from an institutional ethics committee and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}